Abstract: A screen assembly and a rear-projection type graphic display device are provided to block overscanned light Lo projected outside a fresnel lens screen. The screen assembly 20A includes the fresnel lens screen 21, a screen retainer 22 and a light blocking member 23. The fresnel lens screen 21 forms an image on the side of a front surface 21b by image light Le incoming through a back surface 21a. The screen retainer 22 has a back surface 22a whose area is larger than the back surface 21a and the front surface 21b and which is opposed to the front surface 21b to hold it, and a front surface 22b located on opposite side of the back surface 22a to allow an image formed by the image light incoming through the back surface 21a to be visible through the front surface 22b. The screen retainer 22 has an optical transparency. The light blocking member 23 is arranged so as to surround respective side surfaces of the screen 21 in the form of a frame.

Abstract: A projection type display device includes a image displaying element 20 having image display areas 20a, 20b for displaying a plurality of images respectively, a projection optical system 30A having an emitting part for emitting projection light flux to the image display areas 20a, 20b of the image displaying element 20, and a plurality of screens for displaying projected images by the projection light flux transmitted through the image display areas 20a, 20b of the image displaying element 20. In the projection type display device, the image display areas are formed in respective areas in the image displaying element independent of each other. The projected images on the screens correspond to the image display areas, respectively. Each of the screens is arranged in such a position that the each of the screens is not overlapped with shadows of the other screens which are produced since the projection light flux is emitted from the emitting part to the screens.

Abstract: A novel micellar preparation in which the solubility of a sparingly water-soluble anticancer agent has been heightened and which after intravenous administration, enables a high blood concentration to be maintained. The preparation has high medicinal activity and/or is reduced in side effects. The micellar preparation is formed from a block copolymer represented by the following general formula (1): [wherein R1 represents hydrogen or C1-5 alkyl; R2 represents C1-5 alkylene; R3 represents methylene or ethylene; R4 represents hydrogen or C1-4 acyl; R5 represents hydroxyl, optionally substituted aryl C2-8 alkoxyl, substituted C1-4 alkylamino, or amino having a residue of either an amino acid or a peptide derivative; n is an integer of 5 to 1,000; m is an integer of 2 to 300; and x is an integer of 1 to 300; provided that the proportion of hydroxy in the R5's is 0 to 99% and x is not larger than m] and a sparingly water-soluble anticancer agent.

Abstract: A novel micellar preparation in which the solubility of a sparingly water-soluble anticancer agent has been heightened and which after intravenous administration, enables a high blood concentration to be maintained. The preparation has high medicinal activity and/or is reduced in side effects. The micellar preparation is formed from a block copolymer represented by the following general formula (1): [wherein R1 represents hydrogen or C1-5 alkyl; R2 represents C1-5 alkylene; R3 represents methylene or ethylene; R4 represents hydrogen or C1-4 acyl; R5 represents hydroxyl, optionally substituted aryl C2-8 alkoxyl, substituted C1-4 alkylamino, or amino having a residue of either an amino acid or a peptide derivative; n is an integer of 5 to 1,000; m is an integer of 2 to 300; and x is an integer of 1 to 300; provided that the proportion of hydroxy in the R5's is 0 to 99% and x is not larger than m] and a sparingly water-soluble anticancer agent.

Abstract: The present invention relates to a novel fine cisplatin powder utilized as an anticancer agent. The fine cisplatin powder obtained in the present invention does not cause secondary agglomeration, is excellent in fluidity and easily handleable in the pharmaceutical preparation step. Furthermore, the fine cisplatin powder is reduced in the content of N,N-dimethylformamide as the residual solvent, and can be dissolved rapidly in physiological saline, thus being suitable for cancer therapy particularly by intra-arterial injection. This fine powder can be produced by contriving specified means for crystallizing cisplatin from a solution thereof in N,N-dimethylformamide.